Clinical trials, such as the CLEOPATRA trial [60], investigating the combination of these two monoclonal antibodies with chemotherapy for the treatment of HER2+ breast cancer in various settings (metastatic, adjuvant, and neoadjuvant) have demonstrated superior outcomes compared to trastuzumab and chemotherapy combinations alone. Here, ERBB2 is linked to breast cancer.